Peripheral Arterial DiseaseNCT01646801
Study of NMB Drug Ejecting Balloon for Peripheral Arteries
A study testing NMB Balloon Catheter in people with Peripheral Arterial Disease, run by N.M.B. Medical Applications Ltd at 1 site in Israel.
Trial summary
The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral arterial disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peripheral Arterial Disease
- What is being tested?
- NMB Balloon Catheter
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteIsrael
- Study dates
- Jan 2013to Jan 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients 18 years old or older
- Patient with lifestyle limiting claudication or rest pain (Rutherford- Becker scale 2, 3 or 4).
- Patient with de novo lesion or restenotic lesion ≥70% in the iliac, femoral, popliteal or tibial artery.
- The target lesion can be successfully crossed with a guide wire and dilated.
- The target lesion is in a native artery of 2.5-10mm in diameter and less than 80 mm in length.
- Patient is willing to and able to sign a written informed consent and to comply with procedures (e.g., adherence to follow-up visits, including 6 months CT-angiography/MRA follow-up).
Who cannot join
- Women who are pregnant or breast-feeding and women of childbearing potential who do not use adequate contraception.
- Previous participation in another study with any investigational drug or device within the past 30 days.
- The patient is currently enrolled in another investigational device or drug trial.
- Severe reaction to contrast agents that cannot be adequately premedicated prior to procedure.
- Stenosis with corresponding thrombosis treated within 7 days before enrollment.
- Patient with known contraindications for aspirin or other anticoagulant/antiplatelet therapy.
Show all 9Show fewer
- Patient that has co-morbid illness that may result in life expectancy of less than 12 months.
- History of haemorrhagic stroke or gastro-intestinal bleeding within 6 months.
- Patient with major surgery during the 30 days preceding the interventional procedure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Use of NMB Drug Ejecting Balloon for Treatment of Patients With Peripheral Arterial Disease
The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral arterial disease.
- Conditions
- Peripheral Arterial Disease
- Being tested
- NMB Balloon Catheter
- Medical subject headings
- Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NMB Balloon CatheterDevice
patients treated by the NMB's Drug Ejecting Balloon
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | NMB's Paclitaxel Drug ejecting balloon catheter Receives: Device: NMB Balloon Catheter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Late Lumen Loss (LLL)
Late Lumen Loss (LLL) defined as the difference between the minimal luminal diameter after the procedure and at 6 months, as evaluated by Quantitative Angiography (mm units will be used)
Measured: 6 months
Secondary outcomes (3)
Restenosis rate
Restenosis is defined as stenosis of at least 50% of the luminal diameter at 6 months
Measured: 6 months
Device Malfunction
Measured: intraprocedural, 3, 6 and 12 months
Adverse events
Measured: intraprocedural, 3, 6 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2012 (estimated)
- Study startJan 2013
- Primary completionJan 2014 (estimated)
- Study completionJan 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- N.M.B. Medical Applications Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01646801
- Sponsor's protocol ID
- NMB PP CLD 2158
- Status last verified
- Jul 2012
- First submitted
- 16 Jul 2012
- Last updated
- 24 Jul 2012
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Use of NMB Drug Ejecting Balloon for Treatment of Patients With Peripheral Arterial Disease
- ClinicalTrials.gov ID
- NCT01646801
- Acronym / sponsor ID
- NMB PP CLD 2158
- Conditions
- Peripheral Arterial Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- N.M.B. Medical Applications LtdIndustry (pharma, biotech, devices)
- Study start
- Jan 2013
- Primary completion
- Jan 2014 (estimated)
- Study completion
- Jan 2015 (estimated)
- First posted
- 20 Jul 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral arterial disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Device: NMB Balloon CatheterNMB's Paclitaxel Drug ejecting balloon catheter |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients 18 years old or older
- Patient with lifestyle limiting claudication or rest pain (Rutherford- Becker scale 2, 3 or 4).
- Patient with de novo lesion or restenotic lesion ≥70% in the iliac, femoral, popliteal or tibial artery.
- The target lesion can be successfully crossed with a guide wire and dilated.
- The target lesion is in a native artery of 2.5-10mm in diameter and less than 80 mm in length.
Key exclusion criteria (9 listed)
- Women who are pregnant or breast-feeding and women of childbearing potential who do not use adequate contraception.
- Previous participation in another study with any investigational drug or device within the past 30 days.
- The patient is currently enrolled in another investigational device or drug trial.
- Severe reaction to contrast agents that cannot be adequately premedicated prior to procedure.
- Stenosis with corresponding thrombosis treated within 7 days before enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NMB Balloon Catheterpatients treated by the NMB's Drug Ejecting Balloon | Device | Experimental |
Primary outcome
Late Lumen Loss (LLL)
Time frame: 6 months
Late Lumen Loss (LLL) defined as the difference between the minimal luminal diameter after the procedure and at 6 months, as evaluated by Quantitative Angiography (mm units will be used)
3 secondary outcomes
Restenosis rate
Time frame: 6 months
Device Malfunction
Time frame: intraprocedural, 3, 6 and 12 months
Adverse events
Time frame: intraprocedural, 3, 6 and 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2012.
Related trials for Peripheral Arterial Disease
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Active, not recruiting
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
Thrombosis, Arterial Occlusive Diseases
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NMB Balloon Catheter in people with Peripheral Arterial Disease, run by N.M.B. Medical Applications Ltd at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Eli Atar, MD (972-3-9376389, elia@clalit.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Late Lumen Loss (LLL) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2012.